# First Line Osimertinib in the Real World: an Inter-regional Prospective Study

> **NCT04965701** · — · COMPLETED · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 200 (actual)

## Conditions studied

- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib 80 MG

## Key facts

- **NCT ID:** NCT04965701
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-05-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965701, "First Line Osimertinib in the Real World: an Inter-regional Prospective Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04965701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*